Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy BioPharma DiveNews of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive News of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. Neuroscience Read full story Post navigation Previous: Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launchNext: Parexel buys Vitrana to boost patient safety toolkit Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
